Abstract Classical de-afferentation studies, as well as experience-dependent visual plasticity paradigms, have confirmed that both the developing and adult nervous system are capable of unexpected levels of plasticity. This capacity is underscored by the significant spontaneous recovery that can occur in patients with mild-to-moderate impairment following stroke. An evolving model is that an interaction of biological and environmental factors during all epochs post-stroke influences the extent and quality of this plasticity. Here, we discuss data that have implicated specific epigenetic proteins as integrators of environmental influences in 3 aspects of stroke recovery: spontaneous impairment reduction in humans; peri-infarct rewiring in animals as a paradigm for developing therapeutically-driven impairment reduction beyond natural spontaneous recovery; and, finally, classical hippocampal learning and memory paradigms that are theoretically important in skill acquisition for both impairment reduction and compensatory strategies in the rehabilitation setting. Our discussion focuses primarily on B lymphoma Mo-MLV1 insertion region proteins of the polycomb repressive complex, alpha thalassemia/mental retardation syndrome X-linked chromatin remodeling factors, and the best known and most dynamic gene repressors, histone deacetylases. We will highlight exciting current data associated with these proteins and provide promising speculation about how they can be manipulated by drugs, biologics, or noninvasive stimulation for stroke recovery.
Introduction
Stroke is one of the leading causes of disability in the USA. While acute stroke mortality is declining, the number of people living with the sequelae from stroke has increased. Despite the best rehabilitation efforts, 50 % of stroke victims are living with hemiparesis, 35 % are depressed, 26 % are dependent for activities of daily living, and 19 % have aphasia [1] .
Given that just 50 years ago there was little evidence to support that the central nervous system (CNS) could reorganize after injury [2] , the biological repair field has come a long way. In recent years, preclinical research has been pivotal to our understanding of the pathophysiological processes of stroke, and new, sophisticated models have provided the means to develop strategies to interrupt damaging mechanisms, such as oxidative stress, inflammation, excitotoxicity and apoptosis [3] [4] [5] . Translating the successes found in animal models into humans, however, has not been as rewarding. Despite more than 70 neuroprotective agents being tested in over 140 clinical trials, recombinant tissue plasminogen activator, which must be given within 4.5 h of stroke onset [6] , remains the only approved treatment for stroke [3, 7] . In addition to the critical issues such as dose, timing, and specificity of targets that still need elucidation, a logical reason for these failures is that the window of time in which neuroprotective agents must be administered is simply too short. Thus, there has been a burgeoning amount of interest in finding neurorestorative therapies that enhance adaptive neuroplasticity and brain reorganization during the days, weeks, and months that follow brain injury [3, 8] . However, conceptual frameworks that provide a platform on which to combine novel impairment-based restorative therapies with traditional, compensatory therapies, are only just evolving.
Here we present one framework for understanding how current research efforts combine with standard of care to optimize function for patients in the subacute and chronic phases of stroke. This framework can be understood best in the context of the impairments (physiological movement), disabilities (conducting activities to care for self), and handicaps (interactions within society) that occur consequent to stroke [9] . For example, following a stroke in the left middle cerebral artery territory, a patient is left with several impairments, including right hemiparesis. As a result of this right hemiparesis, the patient has an associated disability. For example, he or she will not be able to walk across the room. Traditional, standard rehabilitation approaches focus on treating disability with compensatory strategies, including teaching a patient how to use a wheelchair or to perform a task using the good arm. Compensatory behavioral techniques are absolutely necessary to teach patients how to transfer, walk with assistance, eat, brush their teeth, communicate, and engage secondary preventative measures required to prevent a second stroke. However, these strategies can be seen as inadequate among those who need complete, or nearly complete, reinstatement of premorbid functioning to get back to work, care for their family, and engage in social interactions. In order to optimally reduce disability, novel rehabilitation approaches must include a focus on impairment reduction, and leverage our enormous strides in biological understanding to increase motor recovery, restore language function, and enhance cognition-preferably to the level that patients were at before the stroke. Epigenetic targets represent an area of growing support and interest because they sit at the interface between environmental influences (in this case, stroke-induced injury) and various types of plasticity. Indeed, a major unanswered question in stroke research is how the peri-infarct environment, which includes the glial scar [10] [11] [12] , changes in patient arousal [13] , and dyshomeostasis of glutamate [14] , affect all the distinct domains of plasticity to influence recovery. We will provide some models to illustrate how epigenetic proteins could modulate impairment trajectories after stroke, including peri-infarct plasticity. Finally, we will discuss the epigenetics of learning and memory, as both impairment and compensatory strategies will be shaped by the ability of patients to carry over strategies to relearn old skills and learn new skills (Fig. 1) .
Modulating the Natural History of Impairment After Stroke: A Role for Polycomb Proteins?
Following a stroke, available evidence suggests that for those patients with mild-to-moderate motor or language dysfunction, impairment 3 months after stroke is predicted by the level of impairment early on after stroke (within the first few days) (Fig. 2) [16] [17] [18] . By contrast, among those with severe motor or language impairment, recovery trajectories appear more random [16, 18] . These observations suggest that early environmental injury events simultaneously constrain and direct the amount of impairment reduction that will occur. For those who are mildly-to-moderately affected, the trajectory is seen as independent of post-acute treatment setting, suggesting that currently available, diverse environmental factors beyond the first few days have little impact on the level of impairment reduction that occurs. Some have elegantly and appropriately argued that this is a rationale for focusing acute rehabilitation on impairment reduction, as current post-acute treatment focuses on compensation, possibly at the expense of impairment reduction [15] . We interpret these data somewhat differently through an epigenetic lens. A plausible model is that early injury events (as yet undefined) that predict impairment level soon after stroke, modify proteins above the genome, and are known as epigenetic proteins. Once modified, these proteins can simultaneously govern, but also constrain, the level of impairment reduction that can be achieved by affecting the type and level of plasticity or repair-based gene expression that can occur. The model also predicts a threshold from the transition from moderate-to-severe impairment where epigenetic changes that drive spontaneous, environmentindependent motor recovery disappear in a more random and less predictable way. In other words, the spectrum of nonsevere to severe stroke is accompanied by unpredictable changes in epigenetic proteins that lead to unpredictable recovery. Specifically, some patients with severe stroke experience large gains in recovery, while others do not recover at all (Fig. 2) . Do viable candidates for epigenetic modulators of impairment post-stroke exist and can they be modified for therapeutic benefit? Sublethal injury in the CNS following ischemia engages a series of adaptive genetic changes that can, ultimately, coordinately protect the brain from further injury and simultaneously enhance repair. One family of transcriptional repressors implicated in this response is the polycomb group proteins (PcG), which includes the sex comb on midleg homolog 1 and B lymphoma Mo-MLV1 insertion region (BMI-1) proteins [19] (Fig. 3 ). This complex of proteins can diminish chromatin accessibility by mono-ubiquitinating histone 2A and histone 2B. Histones form core structural motifs of the nucleosome, are repeated every 146 base pairs, and must be unwound to permit transcription. By favoring a more compact chromatin state, the PcG complex proteins appear to function as transcriptional repressors. Among the many genes that they repress, specific subtypes of potassium channels, such as KCNA5 and KCNB2, have been identified [20] . Repression of potassium channels not only leads to decreased consumption of adenosine triphosphate (ATP) (via decreased dependence and utilization of the Na + /K + ATPase to maintain potassium gradients), but can also lead to prolonged action potentials and increased conduction velocity. Indeed, potassium channel blockers, such as dalfampridine (trade name Ampyra) and tetraethylammonium, have been shown not only to protect neurons from apoptosis, but also enhance recovery following stroke in animals [21, 22] . Besides potassium channels, BMI-1/polycomb complex proteins appear to be important in repressing genes involved in senescence in cortical neurons, thereby de-repressing antioxidant and prosurvival genes, and enhancing survival [23] . PcG complex proteins would thus be expected to enhance neural activity (a substrate for recovery) via repression of potassium channels, and endorse the expression of genes that minimize the toxic effects of neural activity, particularly in the acute post-stroke epoch. Of note, BMI-1 proteins and the PcG complex can also drive proliferation of neural stem cells via the ability to repress an endogenous cell cycle inhibitor protein, p16 [24] . Loss of this brake on cell division allows acceleration of production of progenitors. The pleotropic effects of the PCG complex in multiple cell types suggests that increased expression of BMI-1 and the PcG complex could act as a master regulatory "switch" to govern environment independent recovery trajectories in nonsevere strokes, or convert severe stroke trajectories to those that are predictable, positive, and environmentindependent (Figs. 2 and 3). Accordingly, activation of BMI-1 (and by extension the polycomb complex) is a way to coordinately modulate a program of genes involved in protecting and repairing the brain. Such an approach has obvious practical advantages over single drugs that target single genes. It is likely that the highly specific nature of therapies previously tested in human clinical trials has contributed to the failure of developing stroke treatments for diverse populations of patients with varying comorbidities, genetic backgrounds, and lesion locations. Epigenetic targets have the potential to overcome this problem by influencing coordinated sets of genes. the environment (e.g., training, nutrition) or local biological factors to affect plasticity and recovery, either by influencing acquisition of new skills or relearning of old skills. Epigenetic modifiers can also influence learning and memory, independent of their effects on areas proximal to the stroke, and thus also influence impairment reduction and compensation ] known to be induced by sublethal ischemic injury and recovery trajectories. We propose that polycomb repressive complex proteins are induced proportionally to the initial impairment in nonsevere strokes and thus promote and constrain impairment reduction. For patients with severe strokes, polycomb repressive complex proteins are induced more variably because injury in this case is supra-lethal for cells. Accordingly, impairment reduction is more variable. Elegant studies by Krakauer et al. [15] and, Lazar, Marshall et al. [16] have rigorously defined impairment trajectories of motor function post-stroke. It is also possible that differences in trajectories of recovery have little to do with epigenetic modulators and more to do with the variable levels of activity of patients severely affected by stroke. Future studies will distinguish among these models by determining (1) whether the activation of BMI-1 proteins occurs proportionally to acute impairment in nonsevere strokes, and (2) whether activation of BMI-I proteins in severe strokes creates a more predictable trajectory of recovery by enhancing receptiveness to training and diminishing the likelihood of cell injury with severe training
Further environmental influences are, in theory, integrated by epigenetic proteins following proliferation of neural stem cells to determine the type of cell a neural progenitor will become (cortical neuron, olfactory neuron, astrocyte, or oligodendrocyte). It is striking from an epigenetic perspective that these divergent cell types in the CNS with diverse morphologies and associated functions have identical genomes. Differentiation to a neuronal phenotype during development, and possibly postinjury, could be mediated via antagonists of PcG complex proteins known as the Trithorax complex, highlighting the temporal and spatial control that must exist in activating these distinct epigenetic complexes [24] . While, at this point in time, noninvasive stimulation methods, including transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS), are the only known modalities that can provide this level of spatial and temporal control therapeutically, it is interesting to note that hypoxia preconditioning strategies delivered to whole animals and known to induce BMI-1 expression and the PcG complex, enhance restoration of function when applied post-stroke [25] .
The PcG complex is thus a candidate epigenetic target that could affect levels of impairment reduction post-stroke via multiple downstream pathways (see Fig. 3 ). Indeed, methods to modulate PcG activity or levels might be considered a way to "fool" the brain into directing an increased level of impairment reduction than that which is driven by the injury stimulus alone, thereby allowing a greater degree of spontaneously improved function. Moreover, severe injury might involve damage to the PcG complex and thus create enhanced variability in recovery trajectories, as is seen in this patient group (Fig. 2) . We are currently investigating whether the PcG complex is activated in peri-infarct regions post-stroke or in the blood of patients with stroke. The ability of PcG proteins to confer a survival benefit to cortical neurons and simultaneously direct plasticity phenotypes suggest that augmentation of these proteins in the stroke brain could facilitate early, intense retraining which appears to be empirically limited via aberrant glutamate receptor toxicity in animals and humans [26] .
The Age-related Transcriptome After Stroke Highlights Potential Epigenetic Targets for Axonal Growth and Recovery of Function Post-stroke The significant spontaneous impairment recovery that can occur in humans with mild-to-moderate strokes is paralleled by similar functional recovery in animals with small cortical lesions in the motor or sensory cortex [27] . Functional recovery appears to correlate with plasticity in the preserved, periinfarct zone rather than repair of damaged core infarct areas, and involves a combination of impairment reduction and compensatory movement strategies, which both contribute to recovery of function [28] . This plasticity manifests as changes in spine density and axonal sprouting [29, 30] , and corresponding changes in the motor or sensory homunculus (depending on the focus of the lesion) into areas that are undamaged [31] . Numerous studies using noninvasive magnetic brain stimulation mapping have investigated the occurrence of functional organization of the corticomotor projections as a significant mechanisms for restoration of corticospinal conduction and motor recovery after cortical or subcortical stroke [32, 33] . A map shift in the mediolateral axis is consistent with reorganization within contiguous areas of the motor cortex, while anteroposterior shifts indicate recruitment of neighboring nonprimary motor areas such as the premotor cortex or postcentral cortex [34, 35] . Elegant imaging techniques by the laboratories of Dijkhuizen [36, 37] and Murphy [38] have confirmed significant functional magnetic resonance imaging (fMRI) or voltage-sensitive dye responses in the infarct periphery ipsilesional to the stroke in animals. Equally elegant labeling of sprouting axons after stroke in the + ATPase. BMI-1 proteins have also been shown to enhance antioxidant responses and diminish senescence in cortical neurons. Finally, the polycomb repressive complex is also known to repress cell cycle inhibitors in neural progenitors (e.g., p16) to facilitate proliferation of neural progenitors. Collectively, these findings suggest that inducers of B-lymphoma Mo-MLVI insertion region (BMI-1) of the polycomb repressive complex could enhance protection and repair postinjury. The induction of this complex could also facilitate early, intense training which appears to be dose-and intensity-limited because of potential to increase damage after stroke sensory cortex by Carmichael and colleagues has enabled an identification of a gene signature characteristic of growing neurons post-stroke that presumably subserves the fMRI and behavioral improvements that occur [39] .
The studies by Carmichael et al. are the first to highlight the potential importance of specific "epigenetic" proteins in the adaptive plasticity following stroke in vivo, but build on prior in vitro studies on the epigenetics of axonal sprouting from the Langley, DiGiovanni, and Roskams laboratories (all described in this issue). Although a number of epigenetic proteins messenger RNAs are induced in young animals and would be relevant to early brain injury [e.g., histone deacetylase (HDAC)4], there appear to be only two significant "epigenetic" proteins messenger RNAs induced in vivo in the aged brain [HDAC 11 and alpha thalassemia/mental retardation syndrome X-linked (ATRX)]. The best studied of these in the context of stroke recovery is ATRX, a gene with two signature motifs: a plant homeodomain zinc finger domain and a DNA-dependent ATPase domain of the SNF-2 (sucrose nonfermenting) family, a putative ATP-dependent chromatin remodeling protein [40, 41] . These proteins use the energy of ATP hydrolysis to introduce superhelical torsion in DNA, which can then lead to transcriptional activation or repression. Li et al. [39] used loss of function and gain of function approaches to show that ATRX can induce axon outgrowth in vitro and in vivo by rewiring after stroke in the infarct zone [39] (Fig. 4) . Moreover, as ATRX is found only in nuclei, it makes sense that its actions may be related to its ability to enhance or repress expression of specific genes via its chromatin-modifying domain. Recently, however, ATRX has been mutated in a mouse, and a role for ATRX in dendritic spine morphology, but not spine number, was observed, likely via a depression of PP1 phosphatase and increased calmodulin-kinase II activity [43] . While this does seem to substantiate a role of ATRX in dendritic rather than axon growth in development, one cannot exclude a role for this protein in regulating genes necessary for axonal sprouting postinjury. Future studies with these ATRX mutant mice post-stroke should clarify this question. ATRX is part of a super complex of proteins that modify chromatin structure at promoters, large chromatin domains, and even whole chromosomes, and it has been implicated in DNA repair, as well as transcription. Therefore, knocking out the protein could have diverse specific and nonspecific effects (Fig. 4) . Small molecules that target distinct domains in ATRX (particularly the ATPase chromatin-modifying domain) would overcome the nonspecific effects of protein knockdown (because only one domain out of many would be inhibited) and could also complement prior loss of function studies to establish how ATRX enhances axon sprouting in the post- Fig. 4 Li et al. [39] have shown that the adenosine triphosphate (ATP) chromatin-modifying enzyme, alpha thalassemia/mental retardation syndrome X-linked (ATRX) is induced in sprouting neurons post-stroke in the aged rodent, and that ATRX is necessary and sufficient for axon growth. Bioinformatic analysis of the ATRX promoter in a host of species shows striking conservation of the proximal promoter regions through phylogeny. Indeed, there is approximately 90 % conservation in regions of the proximal promoter [-500 base pairs from the transcriptional start site (TSS)]. Conserved binding sites for hepatocyte nuclear factor-4 (HNF), cyclic adenosine monophosphate response element binding protein (CREB), CCAAT box enhancer binding protein, and YY1 are illustrated within the ATRX promoter. Future studies will establish which of these sites is critical for the regulation of ATRX specifically and the sprouting transcriptome generally [39, 42] stroke epoch and whether these effects are mediated via transcriptional regulation or some other function (e.g., DNA repair). It is intriguing to note that ATRX appears to form a complex with MeCP2 and cohesins, 2 chromatin regulators that have been implicated in genetic autism spectrum disorders (ATRX syndrome, Rett, and Cornelia de Lange), diseases which have a common cognitive defect. It appears these proteins are involved in the repression of genes during neurogenesis in development and could be re-expressed in adulthood after injury to accomplish the same goal [44, 45] .
HDAC and HATs in Axonal Sprouting Post-stroke
The most dynamic and readily regulated epigenetic marks appear to be acetylation of lysine groups on the N-terminal tails of histones, as outlined in other articles in this issue. Acetylation of histone tails interdicts electrostatic interactions between histone proteins and DNA, and thus favors a more transcriptionally competent state [46, 47] . As transcription appears to be required for neurite outgrowth, a reasonable model is that small molecules that bias histones toward an acetylated state [histone acetyltransferase activators (see article by Boutillier et al. in this issue [48] ) or HDAC inhibitors (see articles by Di Giovanni et al. [49] , Wagner et al. [50] , and Roskams et al. [51] in this issue)] should enhance neurite outgrowth and stroke recovery. HDAC inhibitors are believed to bias gene expression toward the growth program via effects on nuclear and axonal HDACs. Nuclear HDACs specifically implicated include class I HDACs (isoforms 1, 2, 3, or 8). Recent studies from our own group indicate that a class I HDAC inhibitor, CI-994, which was tested in humans with cancer and found to be safe, has no effect on stroke recovery in rodents when given daily 10 days after stroke, despite clearly augmenting H4 K12 acetylation in the cortex (S. Cho, unpublished observations). The study suggests class I HDAC inhibitors might not be good agents for stroke recovery, but, at this point, the assumption that H4 K12 is a good biomarker to optimize neurite outgrowth is not substantiated. Also, as distinct HDAC isoforms might have different effects in distinct cell types, it is formally possible that isoform-selective inhibitors might provide beneficial effects on functional outcome not seen with more nonselective inhibitors like CI-994. Isoform-selective HDAC inhibitors are discussed thoroughly in other articles in this issue (see Wagner et al. [50] ). A whole battery of HDAC inhibitors is available to test, but one needs biomarkers that reflect activation of the genes of interest [e.g., activity related cytoskeletal protein (Arc ), arginase, brainderived neurotrophic factor (BDNF)] before moving forward to test in humans. Moreover, recent studies suggest that other epigenetic targets may be useful in the post-stroke epoch, including microRNAs [52] .
Neuroplasticity: Hebbian Plasticity and Carry-over in the Rehabilitation Setting
Neuroplasticity is a broad term referring to the ability of the CNS to adapt according to experience, and involves numerous synaptic and nonsynaptic neuronal, as well as non-neuronal processes. More specifically within the context of stroke recovery, plasticity can be subdivided into several types of which the first to be discussed is homeostatic synaptic plasticity. Homeostatic synaptic plasticity refers to the intrinsic adaptive mechanisms that conspire to return synaptic activity to a prior set point in the face of significant perturbations in that activity. In the case of the brain following stroke, one can imagine areas that are hyperexcitable (because of excess glutamate dyshomeostasis) and areas that are hypo-excitable (because of loss of neuronal input). Homeostatic synaptic plasticity refers to the aggregate of common mechanisms that are involved in restoring network activity to the pre-injured state. Spontaneous recovery from stroke thus may be construed as the cardinal manifestation of homeostatic plasticity. Known effectors of homeostasis in this context include BDNF, tumor necrosis factor TNF-α neuronal pentraxin-2 and Arc [53] . While the role of Arc and TNF-α in stroke recovery have yet to be evaluated, gain of function and loss of function of BDNF is known to, respectively, enhance and diminish stroke recovery in models of focal stroke [54, 55] . Moreover, as HDAC 2 has been clearly demonstrated to constrain transcription of BDNF and Arc in some postinjury paradigms, HDAC 2 selective inhibitors may be important in augmenting endogenous mechanisms that allow homeostatic synaptic plasticity to be reestablished [56] . However, this has yet to be examined.
Rather, HDAC 2 has been implicated in a distinct form of plasticity called Hebbian plasticity. This type of plasticity has been glibly referred to as "cells that fire together wire together". More specifically, if a presynaptic neuron fires just before a postsynaptic neuron, that synapse is strengthened out of proportion to other synapses. This type of associative strengthening of synapse activity is thought to underlie motor learning, as well as cognitive learning and memory, and is likely very important for stimulated impairment reduction and learning of compensatory techniques post-stroke. Numerous epigenetic modulators of Hebbian plasticity have been defined, and these offer a host of targets for augmenting the effects of synaptic activity or experience-dependent activity on stroke recovery. The best studied, as described above, is HDAC 2. Over-expression of HDAC 2 has not been examined in the context of motor learning before or after stroke, but rather in terms of hippocampal-based learning and memory paradigms. Of note, overexpression of HDAC 2, but not HDAC 1, leads to deficits in spatial memory, but not shortterm memory or exploration of novel objects [56] . In this context, HDAC 2 binds to and represses a cassette of genes that are necessary for experience dependent plasticity in the hippocampus, including BDNF, Egr-1 , c-fos , cpg-15 , CamKIIa , cyclic adenosine monophosphate responseelement binding protein (CREB ), CREB-binding protein , and N-methyl-D-aspartate receptors. Small-molecule inhibitors of HDAC2, including suberoylanilide hydroxamic acid (SAHA) and sodium butyrate, enhance water maze performance in rodents, consistent with their ability to enhance hippocampal-based learning and memory. These findings suggest that established HDAC inhibitors such as SAHA, which are currently in phase II testing for human cancer, could be used to enhance learning and memory of skill acquisition in the rehabilitation setting, especially in early therapy when executive function (such as knowledge and memory of result) is critical for skill acquisition prior to automation. In this way, they could be seen as augmenters of one's ability to learn compensation or engage in novel training strategies to reduce impairment (Fig. 5) . However, to our knowledge, no-one has specifically examined the role of hippocampal-based plasticity on stroke recovery. Of note, it is interesting that in the dish, dissociated neurons have more robust activation of genes associated with hippocampal Hebbian plasticity when HDAC inhibitors are combined with depolarization or activity [56] . This suggests the possibility that HDAC inhibitors alone can change the propensity of the system toward adaptive plasticity and behavioral improvement, but that propensity will not be realized unless it is paired with the appropriate training or noninvasive cortical stimulation. At this time, the $64,000 question is what part of the brain should be stimulated with a global HDAC inhibitor on board to enhance synaptic efficacy and improve behavioral outcomes. It is reasonable to hypothesize that skill acquisition post-stroke in the rehabilitation setting will be enhanced with class I HDAC inhibition (that includes HDAC2) and noninvasive cortical stimulation of the hippocampal region locally, using deep penetrating magnetic fields (TMS) or focused transcranial electric fields, or indirectly via frontal cortex-hippocampus circuits using a frontal cortex target [57] . It is also reasonable to propose that motor learning might be enhanced by HDAC inhibitors only under conditions where stimulation of the motor cortex or experience are invoked. In our negative studies of class I HDAC inhibitors in stroke recovery in animals (S. Cho, unpublished observations), we did not pair the treatment with noninvasive stimulation or training. Future studies combining epigenetic modifying drugs to enhance the transcription of plasticity genes, along with diffuse expression of optogenetic proteins in an animal model of stroke or in humans with TMS or tDCS, will permit a better understanding of the best regions to stimulate to obtain optimal outcomes in terms of motor function, cognitive function, or compensatory skill acquisition. We should hasten to add that the epigenetic repressor (e.g., HDAC isoform, chromatin modifier of plasticity-based gene expression) will likely be different for hippocampal plasticity vs motor plasticity vs visual plasticity. These unique pathways offer challenges, but also the opportunity for pharmacological specificity. Thus, there is much work left to be done to begin to understand how epigenetic proteins can be modified to enhance plasticity for patient benefit, and which components will need to be targeted to enhance homeostatic vs Hebbian plasticity. Noninvasive brain stimulation could be a tool for measuring and possibly promoting brain response to epigenetic therapies in humans. The extent and responsiveness (excitability) of peri-lesional corticospinal connections can be assessed noninvasively in humans, using realtime MRI-based navigation [58, 59] . This could be a promising method to assess local or network excitability (paired-pulse paradigms) changes associated with agents targeting epigenetic mechanisms. Moreover, noninvasive magnetic (repetitive TMS) and electrical stimulation (tDCS) can alter local and network excitability for a period outlasting the intervention. While transient, these techniques can have associated behavioral improvements [60, 61] . Whether such neuromodulatory techniques could be harnessed to place neural networks into a more permissive state for epigenetic therapies remains an open question, yet it is promising given that evidence exists that altered background network activity using tDCS can affect subsequent plasticity induction using TMS protocols [62] . Further, it is plausible that relatively global brain effects of pharmacologic agents could be focalized to peri-lesional areas using directed noninvasive brain stimulation (by increasing focal susceptibility), to associated network nodes (as established using various imaging techniques-diffusion tensor imaging (DTI), functional connectivity magnetic resonance imaging (fcMRI), functional MRI, positron emission tomography), or to other cortical targets of related executive function (e.g., working memory in dorsolateral prefrontal cortex), cerebellum, or, plausibly, hippocampus using contemporary individualized targeting methods. Finally, the ability for epigenetic therapies in humans to facilitate plasticity could be tested experimentally using associative stimulation paradigms with precisely timed repetitive pulses [63, 64] . In the end, the field of stroke rehabilitation research offers the opportunity to combine small molecule epigenetic modulators with experience-dependent plasticity and noninvasive stimulation to define how to reduce impairment in stroke. And until we are 100 % successful in reducing impairment, strategies to simultaneously enhance compensation for residual impairment will be essential in optimizing function for patients.
Conclusion
Epigenetic proteins offer a finite number of targets that can be manipulated to alter the threshold at which experiencedependent plasticity mechanisms can be engaged for therapeutic benefit in the post-stroke epoch. As discussed in this review, these epigenetic proteins that may constrain and direct spontaneous recovery (e.g., polycomb complex proteins), offer promise for impairment reduction (e.g., ATRX ATPdependent chromatin-modifying enzymes and class I and II HDACs), and provide a strategy for acquisition of new skills (HDAC2 inhibitors in hippocampal based-learning and memory). It is clear that much of the work that has been done in animals needs to be evaluated in humans via postmortem analysis or blood biomarkers, but given the importance of environmental influences on stroke outcome, we expect interest in, and therapeutic benefit from, epigenetics to grow as we endeavor to develop novel biological-based therapies for stroke recovery.
